Get the Stockscreener App
0.6144
1.55%
0.00935
Vistagen Therapeutics Inc stock is traded at $0.6144, with a volume of 431.30K.
It is up +1.55% in the last 24 hours and up +21.66% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$0.605
Open:
$0.5999
24h Volume:
431.30K
Relative Volume:
0.17
Market Cap:
$24.34M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-0.4577
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
+1.55%
1M Performance:
+21.66%
6M Performance:
-82.69%
1Y Performance:
-77.24%
1-Day Range:
$0.595
$0.6152
1-Week Range:
$0.56
$0.6538
52-Week Range:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6144 | 23.97M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Downgrade | Maxim Group | Buy → Hold |
| Dec-17-25 | Downgrade | Stifel | Buy → Hold |
| Dec-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - Financial Times
VTGN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline - marketscreener.com
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline - GlobeNewswire Inc.
Notice of Class Action Lawsuit Against Vistagen Therapeutics - Intellectia AI
Total common shares outstanding of Vistagen Therapeutics, Inc. – BMV:VTGN - TradingView
Tangible book value per share of Vistagen Therapeutics, Inc. – BMV:VTGN - TradingView
UPCOMING DEADLINE: Vistagen Therapeutics, Inc. (VTGN) Securities Fraud Class ActionMarch 16, 2026 Lead Plaintiff Deadline - PR Newswire
Vistagen Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 16, 2026 to Discuss Your RightsVTGN - Finviz
LEVI & KORSINSKY, LLP: TIMELINE OF ALLEGED MISREPRESENTATIONS IN VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION (2026-03-04) - Seeking Alpha
VTGN Earnings History & Surprises | EPS & Revenue Results | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Vistagen Therapeutics, Inc. Revenue Breakdown – BIVA:VTGN - TradingView
CapEx per share of Vistagen Therapeutics, Inc. – BIVA:VTGN - TradingView
Long term debt to total assets ratio of Vistagen Therapeutics, Inc. – BIVA:VTGN - TradingView
Basic earnings per share (basic EPS) of Vistagen Therapeutics, Inc. – BMV:VTGN - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN - ChartMill
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. Investor - GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - ChartMill
Vistagen to Participate in Upcoming Investor Conferences - marketscreener.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
2026-03-03 | VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
Robbins LLP Reminds VTGN Stockholders of The March 16, 2026 Lead Plaintiff DeadlineContact The Firm Today For Information About Leading The Vistagen Therapeutics, Inc. Class Action - ACCESS Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, I - GuruFocus
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 – Company AnnouncementFT.com - Financial Times
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - Sahm
VISTAGEN THERAPEUTICS CLASS ACTION: LEVI & KORSINSKY, LLP EXPLAINS LEAD PLAINTIFF DEADLINE AND PROCESS - TipRanks
Shareholders that lost money on Vistagen Therapeutics, Inc. (VTGN) Urged to Join Class Action – ... - Bluefield Daily Telegraph
Shareholders that lost money on Vistagen Therapeutics, Inc. (VTGN) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesVTGN - ChartMill
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen - GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline - marketscreener.com
2026-02-26 | VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
VTGN SEC FilingsVistagen Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims - TipRanks
VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
LEVI & KORSINSKY, LLP: UNDERSTANDING THE LEGAL FRAMEWORK FOR THE VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION - TipRanks
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen LawsuitVTGN - PR Newswire
Vistagen CEO to give corporate overview at TD Cowen healthcare event - Stock Titan
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED - Sahm
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis - Investing.com UK
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - GuruFocus
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) - marketscreener.com
Holzer & Holzer, LLC Reminds VTGN Investors of the March - GlobeNewswire
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):